TrialAnnals of oncology : official journal of the European Society for Medical Oncology2025

Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.

T B Powles et al.PubMed ↗Publisher ↗

No numbers read from the abstract.